Relapsed and/or Refractory Multiple Myeloma
specificA multiple myeloma that is resistant to three classes of therapeutic agents, including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies.
8
Centers
8
Active Trials
—
Cancer Funding
Top Centers for Relapsed and/or Refractory Multiple Myeloma(8)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 56.2 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 56.2 |
| 3 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 56.2 |
| 4 | Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive Active Research Program | 56.2 |
| 5 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 56.2 |
| 6 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 56.2 |
| 7 | Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program | 56.2 |
| 8 | Boston University Cancer CenterBoston, MA Active Research Program | 56.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →